Pfizer Inc. (PFE)
| Market Cap | 150.98B |
| Revenue (ttm) | 63.63B |
| Net Income (ttm) | 8.03B |
| Shares Out | 5.67B |
| EPS (ttm) | 1.41 |
| PE Ratio | 18.89 |
| Forward PE | 9.04 |
| Dividend | $1.72 (6.46%) |
| Ex-Dividend Date | Jan 24, 2025 |
| Volume | 52,932,033 |
| Open | 26.64 |
| Previous Close | 26.73 |
| Day's Range | 26.54 - 27.24 |
| 52-Week Range | 24.48 - 31.54 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 32.00 (+20.12%) |
| Earnings Date | Apr 30, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $32.0, which is an increase of 20.12% from the latest price.
News
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article...
Pfizer appoints James List to lead development of obesity medicines
Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, which includes development of cardiovascular and obesity medicines.
Final Trades: Pfizer, Paychex and the JEPI
The Investment Committee debates their Final Trades.
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court in Duesseldorf on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna.
Pfizer: It's Time To Play Defensive
Pfizer's revenue has stabilized, and operational efficiency is improving, supporting a "Strong buy" rating with a 6.5% forward dividend yield. The market sentiment in the next few months is likely to ...
2 Attractively Priced, High Yield Stocks For Income Durability As The Market Hits New Highs
Hyperinflation and high interest rates make dividend-paying stocks attractive, providing cash flow and alleviating inflation pressure. Pfizer's 6% yield is appealing despite recent stock declines, wit...
Pfizer Remains A Good Pick For Dividend Investors
Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing 530% to $0.63. Despite modest 2025 guidance, Pfizer's oncology and anti-obes...
Pfizer's CEO says he's got a plan to deal with Trump's tariffs — move overseas drug manufacturing to the US
Pfizer's CEO said he may move manufacturing back to the US in response to Donald Trump's tariffs. Albert Bourla said he was not surprised by Trump's victory in November.
Pfizer Inc. (PFE) TD Cowen 45th Annual Health Care Conference (Transcript)
Pfizer Inc. (NYSE:PFE) TD Cowen 45th Annual Health Care Conference March 3, 2025 10:30 AM ET Company Participants Albert Bourla - Chairman and CEO Conference Call Participants Steve Scala - TD Cowen ...
Pfizer could move outside manufacturing to the US, says CEO
Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to the U.S., if required, as President Donald Trump's administration threatens numerous tariffs on imported good...
5 Relatively Secure And Cheap Dividend Stocks, Yields Upto 8% (March 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
FDA Vaccine Panel Meeting To Discuss Flu Shots Reportedly Canceled
A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vacc...
How To Invest $100,000 Today For A Strong Dividend Snowball Portfolio
Want financial freedom? Here's how to turn $100K into a lifetime of growing passive income. These picks offer the perfect balance of high yield, strong dividend growth, and compounding power. Warren B...
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
HONG KONG , Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a c...
Pfizer names former FDA director Patrizia Cavazzoni as chief medical officer
Pfizer said on Monday former head of FDA's drug center, Patrizia Cavazzoni, will join the drugmaker as chief medical officer.
Pfizer: What The Summit Therapeutics Deal Brings
Pfizer and Summit Therapeutics announced a clinical trial collaboration that involves Pfizer's ADC pipeline and Summit's ivonescimab. Pfizer will conduct combination trials of its vedotin-based ADCs w...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD C...
Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here
Despite significant market events, industrial and tech stocks have had similar returns since 2020, indicating a potential long-term rotation favoring value stocks. Higher inflation and interest rates ...
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational ...
Pfizer: No More Growth - Still A Worthy Dividend Buy
PFE's sell-off triggers a rich dividend yield of 6.73% and double digits capital appreciation prospects, thanks to management's focus to "enhancing long-term shareholder value." Despite the patent cli...
Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports
Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.
Dividend Harvesting Portfolio Week 207: $20,700 Allocated, $2,010.09 In Projected Dividends
The S&P 500 is up 3.96% YTD, and I predict it could reach 7,000 by the end of 2025. The Dividend Harvesting Portfolio reached a new milestone with a 28.65% ROI, generating $2,010.09 in forward annuali...
10 Ideal 'Safer' January Dividend Buys, Out Of 40 Choices From Readers
Before January 31, 2025, my REaders mentioned 40 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about the ReFa/Ro. ...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Why Pfizer's Stock Price Isn't Reflecting Its True Value
Pfizer's EPS and revenue beat my expectations, mainly due to strong sales of its anti-cancer medications. So, Xtandi sales amounted to $565 million in the fourth quarter of 2024, an increase of 79.9% ...